Targeting immune dysregulation in myelodysplastic syndromes

JAMA

Volumn 305, Issue 8, 2011, Pages 814-819

  Olnes, Matthew J ^a,b   Sloand, Elaine M ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; LENALIDOMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; AUTOIMMUNITY; BLOOD CELL COUNT; BONE MARROW BIOPSY; BONE MARROW EXAMINATION; CASE REPORT; CLINICAL FEATURE; CLINICAL PROTOCOL; CYTOGENETICS; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HLA MATCHING; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DYSREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; LEUKOPENIA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PANCYTOPENIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; REMISSION; SKIN BRUISING; STEROID THERAPY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 79951980136     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.194     Document Type: Article

References (50)

1. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536-1542. (Pubitemid 46595689)
2. Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28(17):2847-2852.
3. International Agency for Research on Cancer. Myelodysplastic syndromes. In: Swerdlow SH, Campo E, Harris NL, et al, eds; WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2010.
4. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-4395. (Pubitemid 351377805)
5. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088. (Pubitemid 27132124)
6. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-1803.
7. List A, Dewald G, Bennett J, et al; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465. (Pubitemid 44511560)
8. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
9. Sloand EM, Mainwaring L, Fuhrer M, et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood. 2005;106(3):841-851. (Pubitemid 41076423)
10. + cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia. 2003;17(12):2460-2466.
11. Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood. 2002;100(10):3639-3645. (Pubitemid 35303934)
12. Chamuleau MED, Westers TM, van Dreunen L, et al. Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome. Haematologica. 2009;94(4):496-506.
13. Melenhorst JJ, Eniafe R, Follmann D, Nakamura R, Kirby M, Barrett AJ. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol. 2002;119(1):97-105. (Pubitemid 35176503)
14. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res. 2001;25(12):1075-1083. (Pubitemid 33000488)
15. Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Human anti-idiotypic T cells induced by TCR peptides corresponding to a common CDR3 sequence motif in myelin basic protein-reactive T cells. Int Immunol. 2003;15(9):1073-1080. (Pubitemid 37063206)
16. Risitano AM, Kook H, Zeng W, Chen G, Young NS, Maciejewski JP. Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by V beta CDR3 spectratyping and flow cytometry. Blood. 2002;100(1):178-183. (Pubitemid 35177445)
17. Kook H, Risitano AM, Zeng W, et al. Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens. Blood. 2002;99(10):3668-3675. (Pubitemid 34534537)
18. Plasilova M, Risitano A, Maciejewski JP. Application of the molecular analysis of the T-cell receptor repertoire in the study of immune-mediated hematologic diseases. Hematology. 2003;8(3):173-181. (Pubitemid 36700702)
19. Sloand EM,Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008;26(15):2505-2511.
20. + human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85(11):3183-3190.
21. + regulatory T cells in myelodysplastic syndrome (MDS). Blood. 2007;110(3):847-850.
22. Epling-Burnette PK, Bai F, Painter JS, et al. Reduced natural killer (NK) function associated with highrisk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007;109(11):4816-4824. (Pubitemid 46827777)
23. Sato T, Selleri C, Anderson S, Young NS, Maciejewski JP. Expression and modulation of cellular receptors for interferon-gamma, tumour necrosis factor, and Fas on human bone marrow CD34+ cells. Br J Haematol. 1997;97(2):356-365. (Pubitemid 27224618)
24. Aivado M, Rong A, Stadler M, et al. Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol. 2002;68(4):210-216.
25. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JCY, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007;7(2):118-129. (Pubitemid 46164747)
26. Greiner J, Schmitt A, Giannopoulos K, et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica. 2010;95(7):1191-1197.
27. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MMA. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 1999;59(11):2675-2681. (Pubitemid 29269115)
28. Cilloni D, Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol. 2004;112(1-2):79-84. (Pubitemid 38716252)
29. + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood. 1996;88(9):3522-3527.
30. Wagner KD, Wagner N, Schedl A. The complex life of WT1. J Cell Sci. 2003;116(pt 9):1653-1658. (Pubitemid 36582152)
31. Inoue K, Tamaki H, Ogawa H, et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood. 1998;91(8):2969-2976. (Pubitemid 28227548)
32. Cilloni D, Gottardi E, Messa F, et al; Piedmont Study Group on Myleodysplastic Syndromes. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol. 2003;21(10):1988-1995. (Pubitemid 46606388)
33. Sloand EM, Melenhorst JJ, Tucker ZC, et al. T cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy [published online ahead of print November 19, 2010]. Blood. doi:10.1182/blood- 2010-04-277921.
34. Jonásova A, Neuwirtová R, Cermák J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998;100(2):304-309. (Pubitemid 28131061)
35. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia. 2007;21(7):1436-1441. (Pubitemid 46965284)
36. Killick SB, Mufti G, Cavenagh JD, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with "low-risk" myelodysplasia. Br J Haematol. 2003;120(4):679-684.
37. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol. 1998;102(5):1314-1322. (Pubitemid 28435218)
38. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med. 2002;137(3):156-163. (Pubitemid 34827511)
39. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002;100(5):1570-1574. (Pubitemid 34925129)
40. Sloand EM, Olnes M, Weinstein B, et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions [published online ahead of print November 1, 2010]. J Clin Oncol. 2010;28(35):5166-5173.
41. Yue G, Hao S, Fadare O, et al. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. Leuk Res. 2008;32(4):553-558. (Pubitemid 351255556)
42. Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med. 1999;131(6):401-408. (Pubitemid 29444429)
43. Yazji S, Giles FJ, Tsimberidou AM, et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia. 2003;17(11):2101-2106. (Pubitemid 37428374)
44. Stadler M, Germing U, Kliche KO, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia. 2004;18(3):460-465. (Pubitemid 38425859)
45. Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood. 2003;101(6):2156-2158. (Pubitemid 36302052)
46. Broliden PA, Dahl IM, Hast R, et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica. 2006;91(5):667-670. (Pubitemid 43799466)
47. Bagby GC, Lipton JM, Sloand EM, Schiffer CA. Marrow failure. Hematology Am Soc Hematol Educ Program. 2004:318-336.
48. Ravandi F, O'brien S. Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest. 2006;24(7):718-725. (Pubitemid 44836176)
49. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425. (Pubitemid 44061337)
50. Jädersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26(21):3607-3613.